Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Trius Therapeutics has initiated its first Phase I clinical trial of TR-701, an antibacterial drug candidate intended for treatment of patients with serious gram-positive bacterial infections, including those caused by Methicillin-resistant Staphylococcus aureus and other drug-resistant strains.
Subscribe to our email newsletter
The eighty-eight subject single and multiple ascending dose trial will test tolerability, safety and pharmacokinetics of the oral dosage form of the drug and will compare its properties to those of Zyvox, the only marketed drug in the oxazolidinone class.
TR-701 is a novel oral and IV oxazolidinone antibiotic with potent activity against drug-resistant gram-positive bacterial pathogens including those resistant to Zyvox.
Jeffrey Stein, president and CEO of Trius Therapeutics, said: “In this early clinical trial our goal is to demonstrate the potential of TR-701 to provide patients and clinicians with more convenient dosing and a broader safety margin than the current standard of care.”